The IGSF8 Knockout PaTu 8988t Polyclonal Cells product constitutes a CRISPR/Cas9-edited polyclonal knockout cell population targeting the Immunoglobulin Superfamily Member 8 (IGSF8) gene in the human pancreatic ductal adenocarcinoma cell line PaTu 8988t. This polyclonal population, generated via target-gene disruption, provides a loss-of-function model that avoids clonal artifacts and captures heterogeneous editing outcomes, enabling robust functional genomics studies in a physiologically relevant cancer cell background.
The PaTu 8988t host cell line originates from a liver metastasis of a primary pancreatic adenocarcinoma and carries an activating KRAS mutation, a common driver in pancreatic cancer. This well-characterized line is extensively utilized to dissect mechanisms of pancreatic tumor progression, metastatic colonization, and therapeutic resistance, making it a suitable platform for investigating genes that influence metastatic behavior.
IGSF8, also termed CD316 or EWI-2, is a cell adhesion molecule that integrates into tetraspanin-enriched microdomains by forming stable complexes with CD9 and CD81. This association negatively regulates integrin-mediated cell adhesion and migration, particularly through integrins alpha3beta1 and alpha6beta1. Signaling downstream of IGSF8 involves attenuation of FAK and Src phosphorylation, which in turn reduces activation of the PI3K/AKT and MAPK/ERK cascades. Promoter methylation and TGF-beta pathway activity represent potential regulatory inputs. Consequently, IGSF8 knockout is predicted to derepress these integrin-dependent signaling modules, fostering enhanced cell motility and invasive capacity.
Within the PaTu 8988t cell background, IGSF8 knockout is expected to unmask enhanced integrin-driven motility, generating a model to investigate molecular transitions that promote metastatic progression. The interplay between oncogenic KRAS signaling and loss of IGSF8-mediated adhesion restraint may reveal key mechanisms enabling pancreatic cancer cell dissemination and colonization. This system supports the identification of pathway vulnerabilities that can be exploited for anti-metastatic strategies.
Researchers can employ this IGSF8 polyclonal knockout population in diverse assays to characterize phenotypic and molecular consequences of IGSF8 loss. Typical applications include Transwell migration and invasion assays to quantify metastatic potential, immunofluorescence staining for integrin localization and focal adhesion dynamics, co-immunoprecipitation of CD9/CD81 complexes to confirm tetraspanin web integrity, and immunoblotting for phospho-FAK, phospho-AKT, and phospho-ERK to assess signaling activation. Flow cytometry enables surface profiling of CD9 and CD81, while phospho-protein ELISA kits offer quantitative signaling readouts. These approaches support studies in cancer cell biology, signal transduction, and drug target validation. For additional information or technical support, please contact Ascent Research.
